Search

Displaying results 2851 - 2860 of 10000 in total
  1. Drug

    Efbemalenograstim alfa

    go.drugbank.com/drugs/DB18704
    ApprovedInvestigational

    alfa can stimulate the production of neutrophils and thus reducing the severity and duration of neutropenia. … Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration

  2. Drug

    Marnetegragene autotemcel

    go.drugbank.com/drugs/DB17595
    Approved

    These modified cells differentiate to express functional CD18 protein, restoring leukocyte adhesion and extravasation. … Severe leukocyte adhesion deficiency-I (LAD-I) is a genetic disorder leading to frequent life-threatening infections and high fatality risks among affected pediatric patients.

    Synonyms: Autologous CD34+ cells transduced ex vivo with a lentiviral vector (Chim-CD18-WPRE) encoding the ITGB2 gene, Hematopoietic stem cells modified with a lentiviral vector containing the CD18 (integrin beta 2) gene
  3. Drug

    Protein C

    go.drugbank.com/drugs/DB11312
    ApprovedInvestigational

    It is converted by the thrombin/thrombomodulin-complex on the endothelial cell surface to Activated Protein C (APC). … The Protein C pathway provides a natural mechanism for control of the coagulation system and prevention of excessive procoagulant responses to activating stimuli.

  4. Drug

    Dimercaprol

    go.drugbank.com/drugs/DB06782
    Approved

    In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper. … Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects.

  5. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    Deuteration allows the drug to circumvent extensive oxidative metabolism around the cyclopentyl ring, which increases the duration of the pharmacological activity of deuruxolitinib. … [L51083] Alopecia areata is an autoimmune condition that attacks the hair follicles and leads to unpredictable hair loss in the scalp and other areas of the body.

  6. Drug

    Magnesium malate

    go.drugbank.com/drugs/DB15555
    ApprovedWithdrawn

    Mixtures: Corvite FE, Corvite FE
  7. Drug

    Sulfanilamide

    go.drugbank.com/drugs/DB00259
    ApprovedWithdrawn

    Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.

  8. Drug

    Cabotegravir

    go.drugbank.com/drugs/DB11751
    ApprovedInvestigational

    Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine]. … [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals.

  9. Drug

    Lixisenatide

    go.drugbank.com/drugs/DB09265
    ApprovedInvestigational

    Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). … It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763]

  10. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. … [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data.